Effect of BP 2.94, a histamine H3-receptor agonist prodrug, on different models of colitis

Inflammation Research

Volumn 51, Issue SUPPL.1, 2002, Pages

  Coruzzi, G ^a   Poli, E ^a   Pozzoli, C ^a   Nosalova, V ^b   Grandi, D ^a   Lazzaretti, M ^a   Schunack, W ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BP 2.94; CIPROXIFAN; HISTAMINE H3 RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COLITIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HISTOPATHOLOGY; INTESTINE MUCOSA; MALE; NONHUMAN; RAT; TREATMENT OUTCOME;

ACETIC ACID; ANIMALS; COLITIS; ETHANOL; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; IMIDAZOLES; IMINES; INTESTINAL MUCOSA; MALE; PHENOLS; PRODRUGS; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE H3; TRINITROBENZENESULFONIC ACID;

EID: 0036214425     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Inflammatory bowel disease: Etiology and pathogenesis
2. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis
3. 3 receptor
4. Effects of (R)α-methylhistamine on experimental colitis
5. 3-receptor agonist (R)α-methylhistamine: From alkylaryl to substituted diaryl derivatives
6. 3-receptor antagonist
7. Genomics meets histamine receptors: New subtypes, new receptors
8. A comparative analysis of two models of colitis in rats